MELANOMA · CUTANEOUS
IMMUNE-SENSITIVE / RESISTANCE-PRONE
BRAF/NRAS/NF1 · Immune-Sensitive
BRAF V600E (50%) / NRAS / NF1 / TMB-high
γ₁ = 14.134725141734693 · MELANOMA · BRAF V600E · checkpoint · PD-1 · NRAS ·
CANCER BOARD
NEURO
MELANOMA · CUTANEOUS
Driver
BRAF V600E (50%) / NRAS / NF1 / TMB-high
Coverage
~22/100k · Most immunotherapy-responsive solid tumor
Confidence
STRONG
Open Sorries
⚠ BRAF resistance via MEK/ERK bypass
⚠ Uveal melanoma no systemic control
⚠ Brain metastasis checkpoint resistance
HYPOTHESIS
BRAF V600E → dabrafenib+trametinib (targeted). All subtypes → dual checkpoint (nivo+ipi) — durable response ~50%.
⚠ OPEN: Uveal melanoma — GNAQ/GNA11 no approved targeted therapy
3
Sorries
γ₁
14.134725141734693
CATAN CANCER · SKIN-MELANOMA